-
1 week ago | 
ophthalmologytimes.com | Arshad Khanani |Sydney M Crago |Martin Harp
Author(s):,Arshad Khanani, MD, MA, FASRS, discussed the upcoming Clinical Trials Summit (CTS) 2025 meeting, which has become a key event in the ophthalmology and retina research calendar. This fifth-year anniversary meeting marks a notable expansion, with increased participation from clinicians, researchers, investors, venture capitalists, and Contract Research Organizations (CROs).
-
1 week ago | 
ophthalmologytimes.com | Sydney M Crago
Clinical Trials at the Summit will take place on June 21, 2025 in Las Vegas, Nevada. This invite-only event is now in its fifth year, and will bring together ophthalmologists, industry partners, and thought leaders to discuss the current areas of patient need and the clinical trials that are underway to meet those needs. Among the industry partners who will be in attendance at the event is Ocular Therapeutix, Inc.
-
2 weeks ago | 
ophthalmologytimes.com | Justis P. Ehlers |Sydney M Crago
Non-proliferative diabetic retinopathy (NPDR) continues to be an area of focus for pharmaceutical innovations as patients and ophthalmologists hope for better treatment solutions for this condition. Among those treatments currently in development is OTX-TKI, a tyrosine kinase inhibitor from Ocular Therapeutix. At the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting, Justis P.
-
2 weeks ago | 
ophthalmologytimes.com | Siegfried Priglinger |Sydney M Crago
At the Retina World Congress in Fort Lauderdale, Florida, the Eye Care Network spoke with Siegfried Priglinger, MD. Prof Priglinger is director and chairman of the University Eye Hospital of the Ludwig-Maximilians-Universität, in Munich, Germany. The research he presented at the meeting focused on pediatric patients with inherited retinal diseases (IRDs), with an emphasis on studies into the RPE65 gene. Note: The following conversation has been lightly edited for clarity.
-
2 weeks ago | 
ophthalmologytimes.com | Sydney M Crago
Mark Daly, the Chief Technology Officer at Digital Diagnostics, spoke alongside other experts during a session at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which was held in Salt Lake City, Utah. The session was titled, “AI regulation and implementation in ophthalmology” and took place on Tuesday, May 6, from 8:30-10:15 AM.
-
2 weeks ago | 
ophthalmologytimes.com | Jay Chhablani |Sydney M Crago
Jay Chhablani, MD, from the University of Pittsburgh Medical Center's Vision Institute discusses 3D choroidal vessel segmentation technology. Using advanced Plex elite Zeiss swept-source OCT imaging, his team has created a new tool to visualize and analyze Haller vessels in 3 dimensions – overcoming previous limitations of 2D imaging. Note: The following conversation has been lightly edited for clarity. Ophthalmology Times:Can you speak to the development of this 3-dimensional imaging?
-
3 weeks ago | 
ophthalmologytimes.com | Benjamin Bakall |Sydney M Crago
The TEASE-1 clinical trial examined gildeuretinol in 50 patients with Stargardt disease. Data from this trial was presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which was held in Salt Lake City, Utah. Ophthalmology Times caught up with Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants, and Clinical Assistant Professor at University of Arizona College of Medicine – Phoenix.
-
3 weeks ago | 
ophthalmologytimes.com | Sydney M Crago |J. Arevalo
Johns Hopkins researcher J. Fernando Arevalo, MD, PhD, FACS, FASRS, presents ELEVATUM, a pioneering multicountry study examining faricimab's effectiveness in treating diabetic macular edema among underrepresented minorities. The research focused on 124 patients across 40 centers in the United States, targeting individuals aged 18 and older with type 1 or type 2 diabetes. Note: The following conversation has been lightly edited for clarity.
-
3 weeks ago | 
ophthalmologytimes.com | Marguerite B. McDonald |Jason Bacharach |Sydney M Crago
Dry eye disease is one of the most common conditions that affect patients of all ages and demographics. For ophthalmologists, understanding the treatment options that can best meet the needs of their patients is important to helping those patients find relief from their dry eye symptoms. Among the treatment options is perfluorohexylactane eye drops. At the American Society of Cataract and Refractive Surgery 2025 annual meeting, Marguerite B.
-
3 weeks ago | 
modernretina.com | Jay Chhablani |Sydney M Crago
Jay Chhablani, MD, from the University of Pittsburgh Medical Center's Vision Institute discusses 3D choroidal vessel segmentation technology. Using advanced Plex elite Zeiss swept-source OCT imaging, his team has created a new tool to visualize and analyze Haller vessels in 3 dimensions – overcoming previous limitations of 2D imaging. "We have been focused on choroid for more than a decade.
